Dolutegravir (TIVICAY)

Integrase strand transfer inhibitor (INSTI) antiretroviral

Dolutegravir (TIVICAY)

Forms and strengths
Form: TabletStrength: 5 mg (dispersible tablet), 10 mg, 25 mg, 50 mg
Print

Indication

  • Dolutegravir, combined with other antiretroviral agents, is indicated for the treatment of HIV-1 infection in adults.
  • It is also indicated for integrase-inhibitor-naïve pediatric patients aged 4 weeks and older weighing at least 3 kg, in combination with other antiretrovirals.
  • Alternative combinations that avoid metabolic-inducing drugs should be used where possible in patients with confirmed or suspected resistance to integrase inhibitors.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.